FDA approval clears Freenome test as Abbott prepares U.S. launch
Regulatory clearance for Freenome's blood-based colorectal cancer screening test in older adults sets the stage for Abbott to begin U.S. commercialization this fall. The partnership could unlock near-term revenue potential and validate Freenome's platform, potentially expanding into broader screenings if reimbursement and uptake align.
View signal analysis